In this review:
NSCLC
• Adjuvant therapy decreases brain metastasis risk in EGFR-mutated disease
• Early promising results from neoadjuvant immune checkpoint therapy trials
• Postoperative RT not advised in advanced disease
• Lorlatinib proves superior over crizotinib in ALK-rearranged disease
• Cemiplimab shows benefit in first-line metastatic disease with PD-L1 ≥50%
Prostate cancer: combination therapy beneficial in metastatic disease
Breast cancer
• Drug reduces invasive disease toll in high-risk early disease
• Evolving landscape of immune checkpoint inhibitors in triple-negative disease
• Palbociclib with endocrine therapy for HR+/HER2– early breast cancer
Urothelial carcinoma: combination immune therapy fails to show benefit
Gastro-oesophageal cancers: immune therapies show promising results
Renal cancer: cabozantinib + nivolumab effective as first-line therapy
Endometrial cancer: palbociclib improves survival
Please login below to download this issue (PDF)